A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Clinical trial NCT05372419 · COMPLETED
Trial details
- NCT number
- NCT05372419
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-12
- Primary completion
- 2024-05-03
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.